COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Famotidine 80 mg per day for 3 months. Intervention 2: Control group: Placebo for 3 months.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: History of hospitalization due to COVID-19 At least 20 days from the onset of symptoms, and 7 days from the last day of symptoms passed Diagnosis of cognitive impairment (score 23 or less in MMSE test, or score 22 or less in MoCA test) Age between 18-65
Exclusion criteria
Exclusion criteria: Being psychotic Presence of other psychiatric disorders Using other psychiatric drugs or any drug which can affect cognitive performance History of ECT during past 2 months Presence of thyroid disease Presence of kidney disease Presence of liver disease History of cognitive impairment or dementia Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of cognitive impairment. Timepoint: Baseline and months 1.5 and 3. Method of measurement: by Mini mental state Exam (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed